Ho Tony W 4

4 · CRISPR Therapeutics AG · Filed Mar 12, 2021

Form 4

Period: 2021-03-10

See Remarks

Transactions

Exercise/Conversion
Common Shares
2021-03-10+4,583→ 40,445 total
Tax Payment
Common Shares
2021-03-10$124.15/sh−2,141$265,805→ 38,304 total
Award
Stock Option (Right to Buy)
2021-03-11+23,334→ 23,334 total
Exercise: $133.88Exp: 2031-03-11→ Common Shares (23,334 underlying)
Award
Restricted Stock Units
2021-03-11+9,000→ 9,000 total
→ Common Shares (9,000 underlying)

Footnotes (5)

[F1]This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
[F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F4]This option was granted on March 11, 2021 with respect to 23,334 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021.
[F5]This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Documents

1 file